The approval of Hympavzi makes it the first treatment for both hemophilia A and B to be administered through a pre-filled pen ...

The FDA has approved a new preventive treatment for people with certain types of hemophilia that can reduce bleeding episodes, sometimes down to just a few per year.

The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge ...

H. Lundbeck plans to acquire Longboard Pharmaceuticals in a $2.6 billion deal, the companies announced Monday.

Global Hemostasis Products MarketThe global hemostasis products market is poised for substantial growth, with an estimated valuation of USD 1.58 billion in 2023 and projected to exceed USD 2.65 ...

Following the FDA approval, PFE's Hympavzi becomes the first hemophilia medicine approved in the United States to be ...

All the companies have skin in the game for clotting/bleeding disorders. The BMS-Pfizer Alliance market Factor Xa blood ...

Pfizer announced on Friday that the U.S. Food and Drug Administration has granted approval for its once-weekly injection ...

Pfizer has announced the approval of HYMPAVZI by the US Food and Drug Administration (FDA) for patients with haemophilia A ...

The FDA granted the approval of Hympavzi to Pfizer Inc.

A summary of recent health news includes HIV transmission via organ transplants in Brazil, a reconsideration of Eli Lilly's ...

The US Food and Drug Administration (FDA) on Friday approved US pharma giant Pfizer’s Hympavzi (marstacimab-hncq) for routine ...